Research Progress on Diagnosis and Treatment of B Cell Chronic Lymphoproliferative Disease--Review.
10.7534/j.issn.1009-2137.2018.04.046
- Author:
Yue-Yang LI
1
;
Dong-Zhi HU
2
;
Chen TIAN
3
Author Information
1. Department of Hematology, Tianjin Medical University Cancer Hospital National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy; Tianjin 300060, China.
2. Department of Hematology, Tianjin Medical University Cancer Hospital; National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy,Tianjin 300060, China.
3. Department of Hematology, Tianjin Medical University Cancer Hospital; National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy; Tianjin 300060, China.E-mail: tcgirl2001@sina.com.
- Publication Type:Journal Article
- MeSH:
B-Lymphocytes;
Humans;
Immunophenotyping;
Leukemia, Lymphocytic, Chronic, B-Cell;
Lymphoma, Mantle-Cell;
Waldenstrom Macroglobulinemia
- From:
Journal of Experimental Hematology
2018;26(4):1220-1224
- CountryChina
- Language:Chinese
-
Abstract:
The 2016 world health organization (WHO) classification of B cell chronic lymphoproliferative disease (B-CLPD) includes chronic lymphocytic leukemia (CLL), B prolymphocytic leukemia, (B-PLL), hairy cell leukemia (HCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (LPL/WM). All the above-mentioned diseases are partially similar in cell morphology, immunophenotype and molecular genetics, but significantly different in treatment and prognosis. Currently, many new drugs targeted at cell cycle and apoptosis pathway, such as proteasome inhibitor immune modulators and histone deacetylase inhibitors, have achieved encouraging results in B-CLPD, which bring new hope for patients with B-CLPD. The review will discuss the progress in diagnosis and treatment of B-CLPD in recent years.
